cytarabine liposomal

Cytarabine liposomal is a sustained-release, intrathecal formulation of the antimetabolite chemotherapy agent cytarabine. It is encapsulated in a lipid bilayer (liposome) to allow for prolonged drug release into the cerebrospinal fluid (CSF), maintaining therapeutic levels for up to 14 days and reducing the frequency of administration compared to non-liposomal formulations[5][6]. Cytarabine acts as an S-phase specific antimetabolite by being converted intracellularly into its active metabolite, ara-CTP (cytarabine-5'-triphosphate), which inhibits DNA polymerase and impairs DNA synthesis and repair. This leads to cell death in rapidly dividing cells such as cancer cells[3][5]. The primary indication is for lymphomatous meningitis—lymphoma involving the meninges of the brain and spinal cord[3][6].

Brand names

DepoCyt

Other names

cytarabine liposomeliposomal cytarabineDepoCyt